Bladder Cancer, Clinical Trials, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer
Targeted Drug Development; Bladder Cancer; Prostate and Renal Cancer; Targeted therapies for cancer; Prodrugs; Protoxins; Protease biology; Protease inhibitors; Cancer imaging
Dr. Samuel Denmeade is a professor of oncology and urology at the Johns Hopkins School of Medicine. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer.
Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine.
His research interests include prostate and renal cancer, bladder cancer and targeted drug development.
Dr. Denmeade was named the Carolyn and Bill Stutt Scholar by The Patrick C. Walsh Prostate Cancer Research Fund in 2012.